Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Hae Il Jung, Dongjun Jeong, Sanghee Ji, et al.
Cancer Research and Treatment (2016) Vol. 49, Iss. 1, pp. 246-254
Open Access | Times Cited: 184

Showing 1-25 of 184 citing articles:

Immune checkpoints and their inhibition in cancer and infectious diseases
Lydia Dyck, Kingston H. G. Mills
European Journal of Immunology (2017) Vol. 47, Iss. 5, pp. 765-779
Open Access | Times Cited: 480
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Ioannis Zerdes, Alexios Matikas, Jonas Bergh, et al.
Oncogene (2018) Vol. 37, Iss. 34, pp. 4639-4661
Open Access | Times Cited: 252
Hepatocellular carcinoma in the era of immunotherapy
Hao‐Wen Sim, Jennifer J. Knox
Current Problems in Cancer (2017) Vol. 42, Iss. 1, pp. 40-48
Closed Access | Times Cited: 190
Immune-based therapies for hepatocellular carcinoma
David J. Pinato, Nadia Guerra, Petros Fessas, et al.
Oncogene (2020) Vol. 39, Iss. 18, pp. 3620-3637
Open Access | Times Cited: 181
Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma
Fanhua Kong, Qifa Ye, Xiongying Miao, et al.
Theranostics (2021) Vol. 11, Iss. 11, pp. 5464-5490
Open Access | Times Cited: 134
MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
Anju Phoolchund, Salim I. Khakoo
Cancers (2024) Vol. 16, Iss. 2, pp. 259-259
Open Access | Times Cited: 30
The tumor microenvironment: a key player in multidrug resistance in cancer
Lingnan Meng, Ying Zheng, Hao Liu, et al.
ONCOLOGIE (2024) Vol. 26, Iss. 1, pp. 41-58
Open Access | Times Cited: 16
Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade
Hong Jae Chon, Won Suk Lee, Hannah Yang, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 5, pp. 1612-1623
Open Access | Times Cited: 142
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
Bingxin Zheng, Tingting Ren, Yi Huang, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 134
ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma
Albert C. Y. Chan, Wei Yi Zhang, Ksh Chok, et al.
Annals of Surgery (2019) Vol. 273, Iss. 5, pp. 957-965
Open Access | Times Cited: 122
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Yuqing Cao, Xiaoyu Wang, Tianqiang Jin, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 120
Immunotherapy for Hepatocellular Carcinoma: A 2021 Update
Christo Kole, Nikolaos Charalampakis, Sergios Tsakatikas, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 2859-2859
Open Access | Times Cited: 113
<p>M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer</p>
Lili Cao, Xiaofang Che, Xue-shan Qiu, et al.
Cancer Management and Research (2019) Vol. Volume 11, pp. 6125-6138
Open Access | Times Cited: 111
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
Junyu Long, Jianzhen Lin, Anqiang Wang, et al.
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 96
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
Zuzana Macek Jílková, Caroline Aspord, Thomas Decaens
Cancers (2019) Vol. 11, Iss. 10, pp. 1554-1554
Open Access | Times Cited: 93
Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database
Neil Mehta, Jennifer L. Dodge, John P. Roberts, et al.
American Journal of Transplantation (2017) Vol. 18, Iss. 5, pp. 1206-1213
Open Access | Times Cited: 87
The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
Patrizia Leone, Antonio Giovanni Solimando, Rossella Fasano, et al.
Vaccines (2021) Vol. 9, Iss. 5, pp. 532-532
Open Access | Times Cited: 79
Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment
Amblessed Onuma, Hongji Zhang, Hai Huang, et al.
Gene Expression (2020) Vol. 20, Iss. 1, pp. 53-65
Open Access | Times Cited: 78
Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma
Fei Fan, Keji Chen, Xiaoliang Lü, et al.
Hepatology International (2020) Vol. 15, Iss. 2, pp. 444-458
Closed Access | Times Cited: 78
An RNA–RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity
Yanping Wei, Xuewu Tang, Yibin Ren, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 75
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
Piera Federico, Angelica Petrillo, Pasqualina Giordano, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 3025-3025
Open Access | Times Cited: 71
Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data
Uasim Harkus, Miriam Wankell, Pranavan Palamuthusingam, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 799-815
Closed Access | Times Cited: 53
Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma
Xue-Qin Gong, Ning Liu, Yun-Yun Tao, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 24
Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors
W Kim, Ye Zhou, Vera Simonenko, et al.
NAR Cancer (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 8
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia
Alexander Semaan, Dimo Dietrich, Dominik Bergheim, et al.
Virchows Archiv (2016) Vol. 470, Iss. 2, pp. 185-196
Closed Access | Times Cited: 74
Page 1 - Next Page

Scroll to top